Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Apdn receives 1.6 mil purchase orders to tag textile fibers..good money for this company..
Apdn big spike today up $1:60.......anyone have a clue why? Rode, Foose Micky....anyone out there anymore in this ghost town
Anybody have a clue what’s making Apdn move .??? Foose. Mickey anyone
Anyone have any color on anchin selling almost all of his shares.? Foose rode? Everyone on Stocktwits now?
Nice bump up today close to 10 %
Good news ..looks like we got away from maxim...roth did the deal, no color on them
Astra looking life the leader, now running into a problem should buy some time for Ino.
Did the trials in Korea ever start? How many people were supposed to be or are part of the trial?
President making speech tonight on covid news..ino have a shot?
Jason Carr- August 18, 2020, 6:21 AM EDT
SHARE ON:
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Applied DNA Sciences (APDN), with a price target of $22.00. The company’s shares closed last Monday at $9.48.
According to TipRanks.com, Chen is a 4-star analyst with an average return of 10.7% and a 41.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG
You need dr degree to understand that pr for patent app
Article posted from May...?? Am I missing something from ur post?
I think takis is the one who would need an offering, apdn is supplying the joy juice. And they said they are looking for partners. See what happens, opportunity looks stronger than it was after last pr.
Apdn message board has been dead for 2 weeks will be interesting when mkt opens and people see the news
Business insider had a story today ..apdn and the word vaccine in headline. Probably all it took
Whats going on stock moving
Sanjay know something to come on board.
Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nucleic acid-based therapeutic drug candidates, today announced the appointment of Mr. Sanjay Hurry to Executive Director of Investor Relations and Corporate Communications for the company. In this role, Mr. Hurry will oversee the Company’s outreach with the investment community and report to Dr. James A. Hayward, Chairman, President, and Chief Executive Officer.
“We are thrilled to have Sanjay on board as we work to increase and enhance our engagement with the investor community,” said Dr. Hayward. “His demonstrated success in building strategic communications programs that support business growth and deep understanding of Applied DNA’s business will be key to helping us broaden Wall Street’s awareness of our proprietary PCR-based linear DNA manufacturing platform and its multiple applications across industrial and therapeutic industries, the latter our emerging diagnostics and vaccine development programs.”
Advertisement
Mr. Hurry brings over 20 years of investor relations and corporate communications experience for public companies and with investor relations agencies across a spectrum of diverse industries. For the past five years he served as Vice President at LHA Investor Relations, Applied DNA’s agency of record. He holds a BA from New York University.
Applied DNA Forms Clinical Testing Subsidiary to Maximize Utility of FDA EUA-Approved Linea™ COVID-19 Assay Kit and Expands Utility with Successful EUA Amendment
Published: July 9, 2020 at 6:00 a.m. ET
0
- Subsidiary to Advance Commercial Development of Diagnostic Tests for Virology, COVID-19, Oncology -
Email icon
Facebook icon
Twitter icon
Linkedin icon
Flipboard icon
Print icon
Resize icon
The MarketWatch News Department was not involved in the creation of this content.
Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nucleic acid-based therapeutic drug candidates, today announced the formation of a wholly-owned subsidiary, Applied DNA Clinical Labs, LLC (“ADCL”), dedicated to the commercial development of its tests in Virology, for the detection of COVID-19, and in Oncology, for the detection and enumeration of invasive Circulating Tumor Cells (iCTCs). With the formation of ADCL, the Company is executing on a strategy to expand its market reach through value-added services complementary to a growing portfolio of diagnostic assays attractive to a broader number of qualified labs. ADCL allows Applied DNA to be a direct beneficiary of its own diagnostics development beyond the sales of kits to qualified laboratories, and provides the clinical sampling framework necessary to obtain the data required by State and Federal regulatory authorities to develop and improve diagnostics and vaccines in the face of a pandemic with rapidly shifting genetics and infectious behavior.
In mid-May, Applied DNA received Emergency Use Authorization (“EUA”) for a high sensitivity, high-throughput complex molecular test for SARS-CoV-2, the coronavirus that causes COVID-19. The Linea™ COVID-19 SARS-CoV-2 Assay Kit is a real-time polymerase chain reaction (RT-PCR) test for the qualitative detection of SARS-CoV-2 RNA in respiratory specimens. It provides a high-throughput solution to help laboratories address the urgent need for patient testing during the Coronavirus pandemic.
Advertisement
The Company also announced that the amendment of its EUA was approved by FDA to include extraction and concentration of the viral RNA by a magnetic method of nucleic acid extraction that lends itself easily to high throughput scaling with robotics and diversifies the two extraction methods already covered by the existing EUA. A series of EUA amendments are planned to introduce automation for increased throughput and accuracy, gain approval for additional RNA extraction methods and PCR devices to expand the footprint where our EUA assay can be used, develop point-of-care testing and simplify sample acquisition from patients.
Commenting on the amendment, Dr. James Hayward, president and CEO of Applied DNA, said, “We are extremely grateful to our collaborators at Stony Brook University Hospital and to the FDA for their guidance during the development and validation of our Linea COVID-19 Assay Kit. Our goal is to service the COVID-19 patient community and their families, and to facilitate the reopening of universities and businesses with reliable, well-tested science. The demand for COVID testing is diverse, from asymptomatic patients and those in the early stages of disease, to the commercial imperative to operate.”
The Company believes that as the demand for testing grows and diversifies, the existing approval of the Company’s Linea COVID-19 Assay Kit for use with anterior nasal swabs will facilitate uptake by certified testing labs. As opposed to nasopharyngeal swabs, anterior nasal swabs only enter less than 1 inch into the nose, allowing for sampling with minimal irritation or discomfort. Additionally, anterior nasal swabs may be self-collected at a healthcare location or collected by a healthcare worker.
NOW PLAYING:
California Limits July Fourth Celebrations to Combat Coronavirus Surge
California Limits July Fourth Celebrations to Combat Coronavirus Surge
Visit our Video Center
Dr. Hayward continued, “With anterior nasal swabs, we believe patient compliance is not an issue. This is a simple approach to early testing, repetitive testing if begun early in infection, or high-frequency testing, such as in schools, universities, government office, and companies struggling with reopening. When combined with our high-sensitivity and high-throughput Linea COVID-19 Assay Kit, we believe the combined platform to be well suited to combat both the healthcare and economic challenges of the pandemic.”
ADCL, the Company’s new subsidiary was formed to enable clinical testing of patient specimens using methods developed by the Company’s research teams. Access to clinical specimens will also facilitate more rapid development of improvements and new assays. All of these continuous improvements are designed to help drive sales to other approved testing labs.
ADCL was also formed to facilitate the use and development of the Company’s Liquid Biopsy platform for detecting iCTCs in the blood of cancer patients, far simpler and safer than surgical or needle biopsies, and is already in use under contract in a Phase III clinical trial of a promising drug for the treatment of Stage IV pancreatic cancer. The trial involves 3,000 samples and the quantification of metastatic cancer cells in the blood. Dr. Hayward continued, “Eventually, with the utility of ADCL, we plan to seek regulatory approval for our iCTC assay and add it to the tools used in modern oncology to ensure better patient outcomes.”
Advertisement
The Company has obtained its Permanent Facility Identifier for ADCL, has hired a New York State Licensed Clinical Laboratory Director for Oncology and Virology and Certified Laboratory Scientists, and has applied for a license from the New York State Department of Health.
There can be no assurance that this license will be obtained, or that FDA will maintain the Emergency Declaration that enabled the EUA program for COVID-19 diagnostics. There can be no assurance that the Company will obtain approved 510K status (or other necessary regulatory approval) for its COVID-19 In Vitro Diagnostics in the event that the Emergency Declaration is lifted. In addition, the Company’s iCTC assay is currently limited to RUO (Research Use Only), and there can be no assurance that the Company will obtain the necessary regularly approval for its iCTC assay to expand its use outside of RUO
Little more legit than maxim.. Applied DNA Sciences Rated New Buy at HC Wainwright; PT $18
2020-07-02 10:11:12.215 GMT
By Bloomberg Automation
(Bloomberg) -- HC Wainwright & Co LLC initiated coverage of
Applied DNA Sciences Inc. with a recommendation of buy.
* PT set to $18, implies a 132% increase from last price.
Applied DNA Sciences average PT is $19.50.
From delisting to Russell....
Applied DNA Sciences Set to Join Russell Microcap Index
2020-06-26 11:00:00.440 GMT
Applied DNA Sciences Set to Join Russell Microcap Index
Business Wire
STONY BROOK, N.Y. -- June 26, 2020
Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a
leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables
in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug
candidates, supply chain security, anti-counterfeiting and anti-theft
technology, is set to join the Russell Microcap® Index (the “Index”) at the
conclusion of the 2020 Russell indexes annual reconstitution, effective after
the U.S. market opens on June 29, according to a preliminary list of additions
posted on June 19 to the Russell Reconstitution website.
Membership in the Russell Microcap® Index, which remains in place for one
year, means automatic inclusion in the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell indexes primarily
by objective, market-capitalization rankings and style attributes.
“Inclusion into the Index benefits our shareholders by elevating the Company’s
visibility within the global investment community in a year in which the
opportunities for our linear DNA platform as a means to rapidly manufacture
nucleic acid-based therapies at large scale are potentially enhanced by the
global pandemic. Beyond our COVID-19 development efforts that include the
co-development of vaccine candidates with Takis Biotech and our FDA
EUA-approved diagnostic assay kit, we believe that our linear DNA platform
resides at the cutting edge of modern medicine with applicability to
life-saving therapies, such as engineered T cell (CAR T) therapies and gene
therapies,” said Dr. James A. Hayward, president and CEO of Applied DNA
Sciences.
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment strategies.
Approximately $9 trillion in assets are benchmarked against Russell’s US
indexes. Russell indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell Microcap® Index and the Russell indexes
reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell
website.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain
security, anti-counterfeiting and anti-theft technology, product genotyping,
and pre-clinical nucleic acid-based therapeutic drug candidates.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join
our mailing list.
The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN’, and
its publicly-traded warrants are listed on OTC under ticker symbol ‘APPDW’.
About FTSE Russell:
FTSE Russell is a leading global index provider creating and managing a wide
range of indexes, data and analytic solutions to meet client needs across
asset classes, style and strategies. Covering 98% of the investable market,
FTSE Russell indexes offer a true picture of global markets, combined with the
specialist knowledge gained from developing local benchmarks around the world.
FTSE Russell index expertise and products are used extensively by
institutional and retail investors globally. Approximately $16 trillion is
currently benchmarked to FTSE Russell indexes. For over 30 years, leading
asset owners, asset managers, ETF providers and investment banks have chosen
FTSE Russell indexes to benchmark their investment performance and create
investment funds, ETFs, structured products and index-based derivatives. FTSE
Russell indexes also provide clients with tools for asset allocation,
investment strategy analysis and risk management.
A core set of universal principles guides FTSE Russell index design and
management: a transparent rules-based methodology is informed by independent
committees of leading market participants. FTSE Russell is focused on index
innovation and customer partnership applying the highest industry standards
and embracing the IOSCO Principles. FTSE Russell is wholly owned by London
Stock Exchange Group.
For more information, visit www.ftserussell.com
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements describe Applied DNA’s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of risks and
uncertainties, many of which are beyond the control of Applied DNA. Actual
results could differ materially from those projected due to the possibility of
a failure to make timely payment on its outstanding secured convertible notes
and resulting enforcement by noteholders of remedies on collateral which
includes substantially all of Applied DNA’s assets, its history of net losses,
limited financial resources, limited market acceptance, the uncertainties
inherent in research and development, future clinical data and analysis,
including whether any of Applied DNA’s or its partners therapeutic or
diagnostic candidates will advance further in the preclinical research or
clinical trial process, including receiving clearance from the U.S. Food and
Drug Administration or equivalent foreign regulatory agencies to conduct
clinical trials and whether and when, if at all, they will receive final
approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact
that there has never been a commercial drug product utilizing PCR-produced DNA
technology approved for therapeutic use, the unknown outcome of any
applications or requests to U.S. FDA or equivalent foreign regulatory
agencies, the unknown limited duration of any Emergency Use Authorization
(EUA) approval from U.S. FDA, disruptions in the supply of raw materials and
supplies, and various other factors detailed from time to time in Applied
DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed
on December 12, 2019 and our subsequent quarterly reports on Form 10-Q filed
on February 6, 2020 and May 14, 2020, and other reports we file with the SEC,
which are available at www.sec.gov. Applied DNA undertakes no obligation to
update publicly any forward-looking statements to reflect new information,
events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events, unless otherwise required by law.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20200626005055/en/
Contact:
Investor contact: Sanjay M. Hurry, 212-838-3777, LHA Investor Relations,
shurry@lhai.com
Web:www.adnas.com
Twitter: @APDN
-0- Jun/26/2020 11:00 GMT
To view this story in Bloomberg click here:
https://blinks.bloomberg.com/news/stories/QCJ580MEQTXC
COVID-19 Diagnostic Kits and Therapy Market to Reach $13.9 Billion by 2025- Exclusive Report by Meticulous Research(R)
Published: June 19, 2020 at 1:58 p.m. ET
NS1) Street Insider: Applied DNA Sciences (APDN) LineaRx granted International patent number WO2020118004 titled "AMPLICON EXPRESSION
Hopefully a nice gift for the board members/ friends of Jim